Stifel cuts Boston Scientific stock price target on cyberattack impact
Stifel reduced its price target for Boston Scientific (BSX) to $55 from $60, citing the impact of a cyberattack. The company expects material effects on Q3 2026 and full-year 2026 results, leading to lower revenue projections and revised earnings estimates. Analysts remain divided, with some maintaining buy ratings and others lowering targets due to competitive pressures.
How this was made
The 30-second read
Why it matters
The downgrade adds to a series of analyst target reductions, reinforcing bearish sentiment.
Market read
New analyst target cut provides fresh downside catalyst ahead of upcoming earnings report.
What to watch
Potential insurance recoveries or cost‑cutting measures could mitigate the revenue shortfall.
Background
Stifel revised Boston Scientific's Q3 2026 revenue down ~10% and cut the price target after a cyberattack disrupted operations.
Ticker impact
Stifel lowered its price target for Boston Scientific to $55 from $60 due to a cyberattack impact on Q3 2026 revenue and earnings guidance.
likely downside as investors price in reduced guidance and lower target.
Target cut and revised revenue estimates signal material headwinds; market typically reacts negatively to such analyst actions.
Market effects
Medical device sector may see broader scrutiny of cyber risk exposure.
U.S. healthcare stocks could face short-term pressure.
Limited to Boston Scientific and peers; no global macro effect.
Counterpoint
Some analysts still see upside potential if the cyberattack impact is short-lived and Q4 recovery materializes.
Key entities
- companyBoston Scientific Corp.
Medical device manufacturer impacted by a cyberattack.
- analystStifel
Equity research firm that lowered the price target.
